NVO's CagriSema Outshines Semaglutide in Phase III Diabetes StudyZacks Investment Research • 02/03/26
Citi flags bigger tests ahead after Novo Nordisk diabetes trial successProactive Investors • 02/03/26
Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patientsReuters • 02/02/26
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trialGlobeNewsWire • 02/02/26
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?The Motley Fool • 01/30/26
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?Zacks Investment Research • 01/30/26
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data showsReuters • 01/28/26
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?Zacks Investment Research • 01/27/26